Learn more about Cystatin C at booth #1110
For its sixth consecutive year, Gentian Diagnostics will be participating in the AACC Annual Scientific Meeting & Clinical Lab Expo promoting our automated cystatin C immunoassay. Visit us at booth #1110 to learn more.
Cystatin C - The superior kidney marker1
More than 8000 journal articles have been published on the clinical relevance of cystatin C since it was discovered as a marker of GFR in 1979 by Dr. Anders Grubb. The rising cost pressures faced by health systems has pushed cystatin C into the forefront of biomarkers that could reduce healthcare costs in relation to accurate measurement of for estimating glomerular filtration rate (GFR).
27 years after the first automated assay for cystatin C was developed, Gentian emphasises the unique prognostic and diagnostic value of cystatin C as a marker that:
- Is independent of muscle mass2-8
- Estimates GFR without race-adjustment9
- Correlates well with GFR within the “creatinine blind area”10
- Identifies chronic kidney disease (CKD) earlier than creatinine-based eGFR11
- Helps dose medications with a narrow therapeutic index safely, whilst maintaining efficacy 9,12

Recommended for assessment of Glomerular Filtration Rate(GFR) and kidney function9
Analysing cystatin C and creatinine together can give the physician more accurate information on the patient’s eGFR than creatinine alone. The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) recommend increasing the use of cystatin C combined with creatinine, as a confirmatory assessment of GFR or kidney function to secure unbiased diagnostics.
Gentian Cystatin C Immunoassay
- Particle-Enhanced Turbidimetric Immunoassay
- With avian antibodies for reduced interference
- Can be applied on most automated platforms
- ERM-DA471/IFCC standardized
- FDA 510(k) cleared, CE-marked and IVDR certified
Contact us now for more information
Explore cystatin C in your lab - fill out the form or send an email to marketing@gentian.com for more information about the product and prices.
References:
- Dharnidharka VR et al. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002
- 1–226.KDIGO Guidelines 2012 published in Kidney International Supplements Vol3 Issue 1, Jan 2013
- NCIC Clinical guideline (CG182) updated jan 2015 section 2.1 https://www.nice.org.uk/guidance/cg182/chapter/2-Implementation-getting-started.
- Tangri N et al. Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney Int. 2011
- Grubb A. Cystatin C is Indispensable for Evaluation of Kidney Disease. EJIFCC. 2017
- Björk J et al. Validation of standardized creatinine and cystatin C GFR estimating equations in a large multicentre European cohort of children. Pediatr Nephrol. 2019
- Inker LA et al. Estimating glomerular filtration rate from serum creatinine and cystatin C [published correction appears in N Engl J Med. 2012
- Schaeffner ES et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012
- Ebert N, Shlipak MG. Cystatin C is ready for clinical use. Curr Opin Nephrol Hypertens. 2020
- Lindström V. Low molecular mass proteins as markers for renal function and dialysis efficiency. Doctoral Dissertation, Lund University, 2013.
- Murty MS et al. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian J Nephrol. 2013
- Frazee E et al. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. Am J Kidney Dis. 2017